Who is sponsoring NCT00907257?

NCT00907257 is sponsored by Bausch Health Americas, Inc..

What condition does NCT00907257 study?

NCT00907257 studies Acne Vulgaris.

What drugs are being tested in NCT00907257?

Interventions: benzoyl peroxide wash, Tretinoin gel.

What is the status of NCT00907257?

NCT00907257 is currently COMPLETED.

Last reviewed 2012-02-14 · How we verify

A Clinical Assessment of the Use of RETIN-A MICRO (Tretinoin Gel) Microsphere, 0.04% in a Pump Dispenser and a 5% Benzoyl Peroxide Wash Used in the Morning Compared to the Use of RETIN-A MICRO 0.04% Pump Nightly and a 5% Benzoyl Peroxide Wash in the Morning For the Treatment of Facial Acne Vulgaris

NCT00907257 Phase 4 COMPLETED Results posted

A study to determine if using 2 acne products in the morning is as safe and efficacious as using one product in the morning and one product in the evening.

Details

Lead sponsor	Bausch Health Americas, Inc.
Phase	Phase 4
Status	COMPLETED
Enrolment	247
Start date	2009-02
Completion	2009-09

Conditions

Acne Vulgaris

Interventions

benzoyl peroxide wash
Tretinoin gel

Primary outcomes

Change From Baseline in Total Facial Acne Lesion Count — Baseline to Week 12
Total Facial Acne Lesion Count is the sum of non-inflammatory and inflammatory lesions, plus nodules/cysts. Change from Baseline is calculated as the value after Baseline minus the baseline value, and negative values indicate improvement.

Countries

United States